For example, in patients with a high mass of neoplastic MC, advanced SM, and severe IgE-dependent allergies, combined therapy with a KIT-targeting drug or cladribine and omalizumab may be required to bring MCAS events under control [51]. Here, KIT is linked to allergic disease.